Yang Xuyu, Zhou Xiaoling, Tone Paul, Durkin Marian E, Popescu Nicholas C
Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2089-4262, USA; Section on Cellular Neurobiology, Eunice Kennedy Shriver National Institute of Child Health and Development, Bethesda, MD 2089-4262, USA.
Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2089-4262, USA; Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 2089-4262, USA.
Oncol Lett. 2016 Aug;12(2):1591-1596. doi: 10.3892/ol.2016.4781. Epub 2016 Jun 24.
Human hepatocellular carcinoma (HCC) is one of the most common types of cancer and has a very poor prognosis; thus, the development of effective therapies for the treatment of advanced HCC is of high clinical priority. In the present study, the anti-oncogenic effect of combined knockdown of c-Myc expression and ectopic restoration of deleted in liver cancer 1 (DLC1) expression was investigated in human liver cancer cells. Expression of c-Myc in human HCC cells was knocked down by stable transfection with a Myc-specific short hairpin (sh) RNA vector. DLC1 expression in Huh7 cells was restored by adenovirus transduction, and the effects of DLC1 expression and c-Myc knockdown on Ras homolog gene family, member A (RhoA) levels, cell proliferation, soft agar colony formation and cell invasion were measured. Downregulation of c-Myc or re-expression of DLC1 led to a marked reduction in RhoA levels, which was associated with decreases in cell proliferation, soft agar colony formation and invasiveness; this inhibitory effect was augmented with a combination of DLC1 transduction and c-Myc suppression. To determine whether liver cell-specific delivery of DLC1 was able to enhance the inhibitory effect of c-Myc knockdown on tumor growth , DLC1 vector DNA complexed with galactosylated polyethylene glycol-linear polyethyleneimine was administered by tail vein injection to mice bearing subcutaneous xenografts of Huh7 cells transfected with shMyc or control shRNA. A cooperative inhibitory effect of DLC1 expression and c-Myc knockdown on the growth of Huh7-derived tumors was observed, suggesting that targeted liver cell delivery of DLC1 and c-Myc shRNA may serve as a possible gene therapy modality for the treatment of human HCC.
人类肝细胞癌(HCC)是最常见的癌症类型之一,预后很差;因此,开发有效的晚期HCC治疗方法具有很高的临床优先级。在本研究中,研究了在人肝癌细胞中联合敲低c-Myc表达和异位恢复肝癌缺失1(DLC1)表达的抗癌作用。通过用Myc特异性短发夹(sh)RNA载体稳定转染来敲低人HCC细胞中c-Myc的表达。通过腺病毒转导恢复Huh7细胞中DLC1的表达,并测量DLC1表达和c-Myc敲低对Ras同源基因家族成员A(RhoA)水平、细胞增殖、软琼脂集落形成和细胞侵袭的影响。c-Myc的下调或DLC1的重新表达导致RhoA水平显著降低,这与细胞增殖、软琼脂集落形成和侵袭性的降低有关;DLC1转导和c-Myc抑制联合使用可增强这种抑制作用。为了确定DLC1的肝细胞特异性递送是否能够增强c-Myc敲低对肿瘤生长的抑制作用,将与半乳糖基化聚乙二醇-线性聚乙烯亚胺复合的DLC1载体DNA通过尾静脉注射给予携带用shMyc或对照shRNA转染的Huh7细胞皮下异种移植瘤的小鼠。观察到DLC1表达和c-Myc敲低对Huh7来源肿瘤生长的协同抑制作用,表明DLC1和c-Myc shRNA的靶向肝细胞递送可能作为治疗人类HCC的一种可能的基因治疗方式。